- In October 2024, Aptar Pharma acquired SipNose Nasal Delivery Systems' device technology assets, strengthening its position in the intranasal drug delivery market. SipNose’s devices, designed for targeted delivery within the nasal cavity, will enhance Aptar Pharma's patent portfolio and aid in developing new drug delivery products
- In September 2024, Phillips Medisize, a Molex subsidiary, announced its agreement to acquire Vectura Group, a UK-based CDMO specializing in inhalation drug delivery devices. Vectura's expertise includes the development of dry powder inhalers and metered dose inhalers, enhancing Phillips Medisize’s capabilities in inhalation drug delivery
- In April 2024, Aptar Pharma announced plans to expand its manufacturing facility in Congers, New York, with completion expected by the end of 2024. The expansion will enhance the production of Unidose nasal spray systems by adding moulds and assembly lines in cleanroom environments. The facility is set to be operational by 2025
- In March 2024, Enzymatica’s mouth spray ColdZyme secured CE-certification of Class III from Eurofins, a European-approved notified body for medical devices. The new EU medical device regulation (MDR) aims to improve patient safety by introducing more stringent methods of assessment and market surveillance. However, it has been questioned if the extensive technical documentation requirements of the MDR are suppressing opportunities for early device development
- In June 2024- CHAMPS Group Purchasing (GPO) will distribute the exclusive nosebleed devices developed by CoagCo LLC. CHAMPS GPO will incorporate the Coag it NP7 device within its member contracts
